7-117509123-G-A

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong

The NM_000492.4(CFTR):​c.254G>A​(p.Gly85Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000634 in 1,593,676 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G85R) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.000053 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000065 ( 0 hom. )

Consequence

CFTR
NM_000492.4 missense

Scores

15
3
1

Clinical Significance

Pathogenic practice guideline P:24O:1

Conservation

PhyloP100: 7.71
Variant links:
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 15 uncertain in NM_000492.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr7-117509123-G-T is described in ClinVar as [Pathogenic]. Clinvar id is 53510.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.925
PP5
Variant 7-117509123-G-A is Pathogenic according to our data. Variant chr7-117509123-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 7143.Status of the report is practice_guideline, 4 stars. Variant chr7-117509123-G-A is described in Lovd as [Pathogenic]. Variant chr7-117509123-G-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
CFTRNM_000492.4 linkuse as main transcriptc.254G>A p.Gly85Glu missense_variant 3/27 ENST00000003084.11

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
CFTRENST00000003084.11 linkuse as main transcriptc.254G>A p.Gly85Glu missense_variant 3/271 NM_000492.4 P2P13569-1

Frequencies

GnomAD3 genomes
AF:
0.0000526
AC:
8
AN:
152118
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000118
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000399
AC:
10
AN:
250880
Hom.:
0
AF XY:
0.0000516
AC XY:
7
AN XY:
135624
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000882
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000645
AC:
93
AN:
1441558
Hom.:
0
Cov.:
27
AF XY:
0.0000612
AC XY:
44
AN XY:
718684
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000823
Gnomad4 OTH exome
AF:
0.0000335
GnomAD4 genome
AF:
0.0000526
AC:
8
AN:
152118
Hom.:
0
Cov.:
33
AF XY:
0.0000269
AC XY:
2
AN XY:
74308
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000118
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000108
Hom.:
0
Bravo
AF:
0.0000567
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000349
AC:
3
ExAC
AF:
0.0000659
AC:
8
EpiCase
AF:
0.00
EpiControl
AF:
0.000178

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:24Other:1
Revision: practice guideline
LINK: link

Submissions by phenotype

Cystic fibrosis Pathogenic:10Other:1
Pathogenic, criteria provided, single submitterclinical testingJohns Hopkins Genomics, Johns Hopkins UniversityMay 19, 2021- -
Pathogenic, reviewed by expert panelresearchCFTR2Mar 17, 2017- -
Pathogenic, practice guidelinecurationAmerican College of Medical Genetics and Genomics (ACMG)Mar 03, 2004- -
Pathogenic, no assertion criteria providedliterature onlyOMIMDec 01, 1991- -
not provided, no classification providedliterature onlyGeneReviews-- -
Pathogenic, criteria provided, single submitterclinical testingMendelicsNov 05, 2018- -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 29, 2024This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 85 of the CFTR protein (p.Gly85Glu). This variant is present in population databases (rs75961395, gnomAD 0.009%). This missense change has been observed in individuals with cystic fibrosis and other CFTR-related conditions (PMID: 1710599, 9271620, 15176679, 19885835, 22020151, 23891399, 23974870). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 7143). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CFTR protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CFTR function (PMID: 21998193). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submittercurationLaboratory of Medical Genetics, National & Kapodistrian University of AthensFeb 01, 2024- -
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJan 27, 2022The p.G85E pathogenic mutation (also known as c.254G>A), located in coding exon 3 of the CFTR gene, results from a G to A substitution at nucleotide position 254. The glycine at codon 85 is replaced by glutamic acid, an amino acid with similar properties. This mutation was first described in a pancreatic insufficient individual with cystic fibrosis with a second CFTR mutation in trans (Zielenski J et al. Genomics, 1991 May;10:229-35). This mutation results in failure of protein maturation and chloride conductance, and is associated with a severe disease phenotype (Decaestecker K et al. Eur. Respir. J., 2004 May;23:679-84; Gené GG et al. Hum. Mutat., 2008 May;29:738-49). In a cohort of 201 patients with this mutation, elevated sweat chloride levels, pulmonary disease, and pancreatic insufficiency were reported in the majority of individuals (Sosnay PR et al. Nat. Genet., 2013 Oct;45:1160-7). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Pathogenic, criteria provided, single submittercurationCFTR-FranceJan 29, 2018- -
Pathogenic, criteria provided, single submitterclinical testingMyriad Genetics, Inc.Nov 15, 2019NM_000492.3(CFTR):c.254G>A(G85E) is classified as pathogenic in the context of cystic fibrosis and is associated with the classic form of the disease. Sources cited for classification include the following: PMID 23974870. Classification of NM_000492.3(CFTR):c.254G>A(G85E) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -
not provided Pathogenic:9
Pathogenic, criteria provided, single submitterclinical testingCenter for Pediatric Genomic Medicine, Children's Mercy Hospital and ClinicsNov 24, 2015- -
Pathogenic, no assertion criteria providedclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center-- -
Likely pathogenic, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicJun 25, 2019- -
Pathogenic, no assertion criteria providedclinical testingDiagnostic Laboratory, Department of Genetics, University Medical Center Groningen-- -
Pathogenic, criteria provided, single submitterclinical testingAiLife Diagnostics, AiLife DiagnosticsMar 17, 2022- -
Pathogenic, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoJun 27, 2021This variant has been reported in individuals affected with Cystic Fibrosis and Cystic Fibrosis Related Disorders (CFRD) in the published literature (PMID: 32429104 (2020), 28603918 (2017), 23891399 (2014), 23974870 (2013), 23951356 (2013), 22658665 (2012), 22020151 (2012), 18456578 (2008)). In addition, this variant has been shown to have a damaging effect on CFTR protein function (PMID: 32204475 (2020), 24440181 (2014), 23891399 (2014), 15176679 (2004)). Based on the available information, this variant is classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Feb 07, 2017- -
Pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesAug 28, 2019The CFTR c.254G>A; p.Gly85Glu variant (rs75961395) is reported in multiple unrelated patients diagnosed with cystic fibrosis (Chalkley 1991, Chavez-Saldana 2010, Gallati 2009, Kerem 1997, Ooi 2012, Zielenski 1991, CFTR2 database). However, the clinical presentations of these patients are highly variable, ranging from severe lung disorder and pancreatic insufficiency, to mild respiratory symptoms and pancreatic sufficiency (Chalkley 1991, Kerem 1997). Functional characterization of the variant protein indicates a failure in trafficking to the cell surface (Patrick 2011, Sosnay 2013, Van Goor 2014), due to aberrant integration of the protein in the endoplasmic reticulum (Patrick 2011). The variant is described in the ClinVar database (Variation ID: 7143) and in the Genome Aggregation Database in 12 out of 276578 alleles. The glycine at residue 85 is highly conserved, and computational algorithms (Mutation Taster, PolyPhen-2, SIFT) predict that the variant has a deleterious impact on the protein. Considering available information, the variant is classified as pathogenic. References: Link to CFTR2 database: http://cftr2.org/ Chalkley G et al. A cystic fibrosis patient who is homozygous for the G85E mutation has very mild disease. J Med Genet. 1991 28(12):875-7. Chavez-Saldana M et al. CFTR allelic heterogeneity in Mexican patients with cystic fibrosis: implications for molecular screening. Rev Invest Clin. 2010 62(6):546-52. Gallati S et al Cystic fibrosis transmembrane conductance regulator mutations in azoospermic and oligospermic men and their partners. Reprod Biomed Online. 2009 19(5):685-94. Kerem B et al. A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype. Pediatrics. 1997 100(3):E5. Ooi C. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros. 2012 11(5):355-62. Patrick A et al. Alteration of CFTR transmembrane span integration by disease-causing mutations. Mol Biol Cell. 2011 22(23):4461-71. Sosnay PR et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013 45(10):1160-7. Van Goor F et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014 13(1):29-36. Zielenski J et al. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991 May;10(1):229-35. -
CFTR-related disorder Pathogenic:2
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Mar 17, 2017- -
Pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesAug 13, 2024The CFTR c.254G>A variant is predicted to result in the amino acid substitution p.Gly85Glu. This variant has been reported in unrelated patients with cystic fibrosis, pancreatic insufficiency, and congenital bilateral absence of vas deferens (Chalkley et al. 1991. PubMed ID: 1757965; Gallati et al. 2009. PubMed ID: 20021716; Ooi and Durie. 2012. PubMed ID: 22658665; Masson et al. 2013. PubMed ID: 23951356; Sosnay et al. 2013. PubMed ID: 23974870; cftr2.org). Functional studies showed that the p.Gly85Glu substitution leads to defects in CFTR protein processing resulting from the aberrant integration into the endoplasmic reticulum membrane and failure in trafficking to the cell surface (Patrick et al. 2011. PubMed ID: 21998193; Van Goor et al. 2014. PubMed ID: 23891399). This variant is reported in 0.0078% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. -
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor Genetics-- -
Cystic fibrosis;C0238339:Hereditary pancreatitis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation;C2749757:Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsMar 14, 2022- -
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 11, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.99
BayesDel_addAF
Pathogenic
0.40
D
BayesDel_noAF
Pathogenic
0.54
CADD
Pathogenic
29
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.93
.;D;.;.;D;.
Eigen
Pathogenic
0.90
Eigen_PC
Pathogenic
0.87
FATHMM_MKL
Pathogenic
0.97
D
LIST_S2
Uncertain
0.89
D;D;D;D;D;D
M_CAP
Pathogenic
0.76
D
MetaRNN
Pathogenic
0.92
D;D;D;D;D;D
MetaSVM
Pathogenic
0.94
D
MutationAssessor
Pathogenic
3.0
.;M;.;.;.;M
MutationTaster
Benign
1.0
A;A
PrimateAI
Uncertain
0.78
T
PROVEAN
Pathogenic
-7.4
D;D;.;.;D;.
REVEL
Pathogenic
0.94
Sift
Pathogenic
0.0
D;D;.;.;D;.
Sift4G
Pathogenic
0.0
D;D;.;.;D;.
Polyphen
0.99
.;D;.;.;.;.
Vest4
0.97
MVP
1.0
MPC
0.012
ClinPred
0.90
D
GERP RS
5.7
Varity_R
0.99
gMVP
0.98

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.12
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs75961395; hg19: chr7-117149177; API